BiondVax Pharma (BVXV) Reports Q3 EPS of NIS0.00
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BiondVax Announces Third Quarter 2015 Financial Results and Update
November 9, 2015 7:01 AM ESTNES ZIONA, Israel, Nov. 9, 2015 /PRNewswire/ --Â BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the third quarter of 2015 and provided a business update.
Third Quarter 2015 Financial SummaryResults are in New Israel Shekels (NIS) and a translation to US$ is provided, using the exchange rate of 3.923 as at September 30, 2015.
Total operating expenses were NIS 2.21m ($563,000) compared with NIS 1.96m in the third... MoreBiondVax Announces Upcoming Investor Events: Presenting at the LD Micro Conference in Los Angeles Following Investor Non-deal Roadshow
November 5, 2015 7:00 AM ESTNESS ZIONA, Israel, November 5, 2015 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the Company's CEO, Dr. Ron Babecoff, will be meeting with US and Canadian investors on the week of November 9-13, 2015. Over the course of that week, Dr. Babecoff will be visiting New York, Boston, Chicago and Toronto.
On December 2-3, 2015, Dr. Babecoff will be attending and presenting at the LD Micro Conference taking place at the Luxe Sunset Hotel in Los Angeles. This will provide investors... More
